Logo image of FATE

FATE THERAPEUTICS INC (FATE) Stock Fundamental Analysis

NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD

1.25  -0.03 (-2.34%)

After market: 1.24 -0.01 (-0.8%)

Fundamental Rating

3

Taking everything into account, FATE scores 3 out of 10 in our fundamental rating. FATE was compared to 556 industry peers in the Biotechnology industry. While FATE seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, FATE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FATE has reported negative net income.
FATE had a negative operating cash flow in the past year.
FATE had negative earnings in each of the past 5 years.
In the past 5 years FATE always reported negative operating cash flow.
FATE Yearly Net Income VS EBIT VS OCF VS FCFFATE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -44.12%, FATE is in line with its industry, outperforming 53.96% of the companies in the same industry.
FATE's Return On Equity of -60.98% is in line compared to the rest of the industry. FATE outperforms 59.71% of its industry peers.
Industry RankSector Rank
ROA -44.12%
ROE -60.98%
ROIC N/A
ROA(3y)-37.99%
ROA(5y)-32.97%
ROE(3y)-53.45%
ROE(5y)-47.34%
ROIC(3y)N/A
ROIC(5y)N/A
FATE Yearly ROA, ROE, ROICFATE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

FATE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FATE Yearly Profit, Operating, Gross MarginsFATE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.
FATE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FATE has been increased compared to 5 years ago.
There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FATE Yearly Shares OutstandingFATE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
FATE Yearly Total Debt VS Total AssetsFATE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

FATE has an Altman-Z score of -5.10. This is a bad value and indicates that FATE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.10, FATE is doing worse than 60.61% of the companies in the same industry.
FATE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.1
ROIC/WACCN/A
WACC9.75%
FATE Yearly LT Debt VS Equity VS FCFFATE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 8.81 indicates that FATE has no problem at all paying its short term obligations.
FATE has a Current ratio of 8.81. This is in the better half of the industry: FATE outperforms 73.38% of its industry peers.
FATE has a Quick Ratio of 8.81. This indicates that FATE is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.81, FATE is doing good in the industry, outperforming 73.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.81
Quick Ratio 8.81
FATE Yearly Current Assets VS Current LiabilitesFATE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

FATE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.40%, which is quite impressive.
Looking at the last year, FATE shows a very strong growth in Revenue. The Revenue has grown by 106.07%.
FATE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.00% yearly.
EPS 1Y (TTM)22.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
Revenue 1Y (TTM)106.07%
Revenue growth 3Y-37.51%
Revenue growth 5Y5%
Sales Q2Q%-15.38%

3.2 Future

Based on estimates for the next years, FATE will show a small growth in Earnings Per Share. The EPS will grow by 7.04% on average per year.
FATE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.26% yearly.
EPS Next Y16.6%
EPS Next 2Y9.28%
EPS Next 3Y8.64%
EPS Next 5Y7.04%
Revenue Next Year-64.55%
Revenue Next 2Y-53.49%
Revenue Next 3Y-41.14%
Revenue Next 5Y30.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FATE Yearly Revenue VS EstimatesFATE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
FATE Yearly EPS VS EstimatesFATE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FATE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FATE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FATE Price Earnings VS Forward Price EarningsFATE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FATE Per share dataFATE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.28%
EPS Next 3Y8.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FATE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FATE THERAPEUTICS INC

NASDAQ:FATE (7/24/2025, 8:00:02 PM)

After market: 1.24 -0.01 (-0.8%)

1.25

-0.03 (-2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners92.7%
Inst Owner Change-0.26%
Ins Owners1.53%
Ins Owner Change0%
Market Cap143.29M
Analysts75.29
Price Target5.46 (336.8%)
Short Float %8.6%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.17%
Min EPS beat(2)0.25%
Max EPS beat(2)18.09%
EPS beat(4)4
Avg EPS beat(4)14.88%
Min EPS beat(4)0.25%
Max EPS beat(4)31.92%
EPS beat(8)8
Avg EPS beat(8)13.96%
EPS beat(12)12
Avg EPS beat(12)18.97%
EPS beat(16)14
Avg EPS beat(16)15.69%
Revenue beat(2)2
Avg Revenue beat(2)34.32%
Min Revenue beat(2)28.81%
Max Revenue beat(2)39.83%
Revenue beat(4)4
Avg Revenue beat(4)141.82%
Min Revenue beat(4)28.81%
Max Revenue beat(4)371.26%
Revenue beat(8)7
Avg Revenue beat(8)83.66%
Revenue beat(12)10
Avg Revenue beat(12)77.28%
Revenue beat(16)14
Avg Revenue beat(16)78.79%
PT rev (1m)-2.63%
PT rev (3m)-10.06%
EPS NQ rev (1m)3.18%
EPS NQ rev (3m)11.3%
EPS NY rev (1m)-1.44%
EPS NY rev (3m)11.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.27%
Revenue NY rev (1m)1.68%
Revenue NY rev (3m)6.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.75
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.12
BVpS2.52
TBVpS2.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.12%
ROE -60.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.99%
ROA(5y)-32.97%
ROE(3y)-53.45%
ROE(5y)-47.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.53%
Cap/Sales 13.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.81
Quick Ratio 8.81
Altman-Z -5.1
F-Score6
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)98.67%
Cap/Depr(5y)264.44%
Cap/Sales(3y)17.33%
Cap/Sales(5y)31.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
EPS Next Y16.6%
EPS Next 2Y9.28%
EPS Next 3Y8.64%
EPS Next 5Y7.04%
Revenue 1Y (TTM)106.07%
Revenue growth 3Y-37.51%
Revenue growth 5Y5%
Sales Q2Q%-15.38%
Revenue Next Year-64.55%
Revenue Next 2Y-53.49%
Revenue Next 3Y-41.14%
Revenue Next 5Y30.26%
EBIT growth 1Y12.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.92%
EBIT Next 3Y-10.96%
EBIT Next 5YN/A
FCF growth 1Y48.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.95%
OCF growth 3YN/A
OCF growth 5YN/A